CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits

Se Yeong Oh, Hyun Jung Kang, Young Sook Kim, Hyunggee Kim, Young Chang Lim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

CD44 is generally accepted as a surrogate marker for head and neck squamous carcinoma cancer stem cells (HNSC CSCs) and only CD44+ HNSC cells have tumour initiating capacity. However, a recent report suggested that CSCs themselves might be heterogenous due to various genetic alterations. Here, we compared in vitro stem-like cell characteristics, chemoresistance and in vivo tumour formation capacity of CD44+ and CD44- HNSC cells obtained from primary HNSC patient specimens. CD44- HNSC spheroid cells generated spheroid cells again after seeding of single-dissociated spheroid CD44- HNSC cells. Immunocytochemistry assays revealed that various stem cell markers, including octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2) and nestin were up-regulated in CD44- spheroid cells, similar to CD44+ spheroid cells. Furthermore, CD44- spheroid cells appeared to be chemoresistant to cisplatin and showed increased levels of ABCG2, similar to CD44+ spheroid cells. Of most interest, as few as 1000 CD44- spheroid cells were able to give rise to tumours in nude mice. The collective data indicate that the cell surface marker CD44 cannot be used as a selective marker of spheroid-forming, tumour-initiating or chemoresistant cell populations, and further indicate the limitation of current HNSC CSC identification methods using the CD44 cell surface marker.

Original languageEnglish
Pages (from-to)272-280
Number of pages9
JournalEuropean Journal of Cancer
Volume49
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Stem Cells
Neoplastic Stem Cells
Carcinoma, squamous cell of head and neck
Squamous Cell Carcinoma
Octamer Transcription Factors
Neck
Head
Nestin
Neoplasms
Nude Mice
Cisplatin
Biomarkers
Immunohistochemistry

Keywords

  • Biomarkers
  • CD44
  • Head and neck neoplasm
  • Neoplastic stem cell

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits. / Oh, Se Yeong; Kang, Hyun Jung; Kim, Young Sook; Kim, Hyunggee; Lim, Young Chang.

In: European Journal of Cancer, Vol. 49, No. 1, 01.01.2013, p. 272-280.

Research output: Contribution to journalArticle

Oh, Se Yeong ; Kang, Hyun Jung ; Kim, Young Sook ; Kim, Hyunggee ; Lim, Young Chang. / CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits. In: European Journal of Cancer. 2013 ; Vol. 49, No. 1. pp. 272-280.
@article{2f74e6f3e75b44debab58a65ef31fab7,
title = "CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits",
abstract = "CD44 is generally accepted as a surrogate marker for head and neck squamous carcinoma cancer stem cells (HNSC CSCs) and only CD44+ HNSC cells have tumour initiating capacity. However, a recent report suggested that CSCs themselves might be heterogenous due to various genetic alterations. Here, we compared in vitro stem-like cell characteristics, chemoresistance and in vivo tumour formation capacity of CD44+ and CD44- HNSC cells obtained from primary HNSC patient specimens. CD44- HNSC spheroid cells generated spheroid cells again after seeding of single-dissociated spheroid CD44- HNSC cells. Immunocytochemistry assays revealed that various stem cell markers, including octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2) and nestin were up-regulated in CD44- spheroid cells, similar to CD44+ spheroid cells. Furthermore, CD44- spheroid cells appeared to be chemoresistant to cisplatin and showed increased levels of ABCG2, similar to CD44+ spheroid cells. Of most interest, as few as 1000 CD44- spheroid cells were able to give rise to tumours in nude mice. The collective data indicate that the cell surface marker CD44 cannot be used as a selective marker of spheroid-forming, tumour-initiating or chemoresistant cell populations, and further indicate the limitation of current HNSC CSC identification methods using the CD44 cell surface marker.",
keywords = "Biomarkers, CD44, Head and neck neoplasm, Neoplastic stem cell",
author = "Oh, {Se Yeong} and Kang, {Hyun Jung} and Kim, {Young Sook} and Hyunggee Kim and Lim, {Young Chang}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2012.06.004",
language = "English",
volume = "49",
pages = "272--280",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits

AU - Oh, Se Yeong

AU - Kang, Hyun Jung

AU - Kim, Young Sook

AU - Kim, Hyunggee

AU - Lim, Young Chang

PY - 2013/1/1

Y1 - 2013/1/1

N2 - CD44 is generally accepted as a surrogate marker for head and neck squamous carcinoma cancer stem cells (HNSC CSCs) and only CD44+ HNSC cells have tumour initiating capacity. However, a recent report suggested that CSCs themselves might be heterogenous due to various genetic alterations. Here, we compared in vitro stem-like cell characteristics, chemoresistance and in vivo tumour formation capacity of CD44+ and CD44- HNSC cells obtained from primary HNSC patient specimens. CD44- HNSC spheroid cells generated spheroid cells again after seeding of single-dissociated spheroid CD44- HNSC cells. Immunocytochemistry assays revealed that various stem cell markers, including octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2) and nestin were up-regulated in CD44- spheroid cells, similar to CD44+ spheroid cells. Furthermore, CD44- spheroid cells appeared to be chemoresistant to cisplatin and showed increased levels of ABCG2, similar to CD44+ spheroid cells. Of most interest, as few as 1000 CD44- spheroid cells were able to give rise to tumours in nude mice. The collective data indicate that the cell surface marker CD44 cannot be used as a selective marker of spheroid-forming, tumour-initiating or chemoresistant cell populations, and further indicate the limitation of current HNSC CSC identification methods using the CD44 cell surface marker.

AB - CD44 is generally accepted as a surrogate marker for head and neck squamous carcinoma cancer stem cells (HNSC CSCs) and only CD44+ HNSC cells have tumour initiating capacity. However, a recent report suggested that CSCs themselves might be heterogenous due to various genetic alterations. Here, we compared in vitro stem-like cell characteristics, chemoresistance and in vivo tumour formation capacity of CD44+ and CD44- HNSC cells obtained from primary HNSC patient specimens. CD44- HNSC spheroid cells generated spheroid cells again after seeding of single-dissociated spheroid CD44- HNSC cells. Immunocytochemistry assays revealed that various stem cell markers, including octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2) and nestin were up-regulated in CD44- spheroid cells, similar to CD44+ spheroid cells. Furthermore, CD44- spheroid cells appeared to be chemoresistant to cisplatin and showed increased levels of ABCG2, similar to CD44+ spheroid cells. Of most interest, as few as 1000 CD44- spheroid cells were able to give rise to tumours in nude mice. The collective data indicate that the cell surface marker CD44 cannot be used as a selective marker of spheroid-forming, tumour-initiating or chemoresistant cell populations, and further indicate the limitation of current HNSC CSC identification methods using the CD44 cell surface marker.

KW - Biomarkers

KW - CD44

KW - Head and neck neoplasm

KW - Neoplastic stem cell

UR - http://www.scopus.com/inward/record.url?scp=84871417680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871417680&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.06.004

DO - 10.1016/j.ejca.2012.06.004

M3 - Article

C2 - 22770891

AN - SCOPUS:84871417680

VL - 49

SP - 272

EP - 280

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -